Orthobiologics Market

Report Overview

The global orthobiologics market was pegged at US$ 5.44 billion in 2020 and is expected to witness a CAGR of 5.4% during the forecast period. 

Market Fundamentals

Orthobiologics are made from substances that are naturally found in the body or using synthetic substances. They are used by orthopedic surgeons for the rapid healing of injuries. They help in the healing of broken bones, tendons, injured muscles, joints, and ligaments. The term, "orthobiologics" is derived from the combination of two words- ortho referring to the bones, muscles, joints, and tendons, and biologics, which means substances that are naturally or synthetically derived that have properties for healing orthopedic tissues. Common orthobiologics include bone marrow concentrate, platelet-rich plasma, fat grafts, and birth tissues. Orthobiologics have played a key role in revolutionizing orthopedic care.

[88888]

Market Dynamics

Several factors contributing to the growth of orthobiologics market include the rising incidence of sports injuries and the increasing number of road accidents. The rising geriatric population globally and the growing number of people suffering from arthritis and other spine-related disorders are among the key factors boosting the growth of the global orthobiologics market. Moreover, the rising prevalence of arthritis and spinal disorders and the increasing awareness and preference for minimally invasive practices are also playing a pivotal role in propelling the global orthobiologics market growth. However, the high cost of biologics-based treatments and the chances of severe side effects are some of the factors hindering the orthobiologics market growth to a certain extent. The potential risk of infection, no osteogenic potential, or potential host rejection are some of the other disadvantages of using orthobiologics.

Market Ecosystem

The global orthobiologics market has been analyzed from four perspectives: Product, Application, End User, and Region. 

Orthobiologics Market by Product 

Based on product, the orthobiologics market has been segmented into viscosupplementation products, synthetic bone substitutes, demineralized bone matrices, bone morphogenic protein, allografts, stem cells, and others. Viscosupplementation products held the largest share of the orthobiologics market in 2020. The large market share of this segment can be attributed to the rising geriatric population, the rising incidence of arthritis, and the growth in lifestyle-related disorders such as obesity. 

Orthobiologics Market by Application

Based on application, the market has been segmented into osteoarthritis & degenerative arthritis, spinal fusion, fracture recovery, soft-tissue injuries, and maxillofacial & dental applications. The osteoarthritis & degenerative arthritis segment held a large share of the global orthobiologics market. The rising incidence of arthritis, clinical advancements in osteoarthritis management methodologies with growing clinical evidence validating the efficacy of biologics in osteoarthritis treatment, and raising awareness of the use of orthobiologics for its treatment are likely to fuel the growth of this segment. 

Orthobiologics Market by End User

[99999]

Based on end user, the market has been segmented into hospitals & orthopedic clinics, ambulatory care centers, research & academic institutes, and dental clinics & facilities.  The hospitals & orthopedic clinics segment held the largest market share of the market in 2020. Hospitals & orthopedic clinics or centers being the first preference among the population suffering from joint, bone, or muscle-related problems is one of the major factors propelling the segmental growth. Furthermore, the presence of skilled professionals is also expected to boost the growth the market

Orthobiologics Market by Region

Regionally, the global orthobiologics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America dominated the market for orthobiologics holding the largest market share in 2020. Factors driving the regional growth include the rising geriatric population, increasing incidence of arthritis, better reimbursement policies, and growing preference for minimally invasive procedures among the population. Moreover, the rising incidence of sports-related injuries and growing awareness of the use of orthobiologics are some of the other factors boosting the market growth in this region. Furthermore, the dense presence of the prominent players and new product launches have also played a pivotal role in propelling the growth of orthobiologics market in this region. The Asia-Pacific region is expected to witness the fastest growth in the market owing to rising in the geriatric population and a surge in obesity.

Competitive Landscape

Some of the prominent players operating in the global orthobiologics market include:- 

• Medtronic
• DePuy Synthes
• Stryker
• Zimmer Biomet
• Orthofix Medical Inc.
• Smith & Nephew
• Bone Biologics Corp.
• Globus Medical, Bioventus
• RTI Surgical, among others

Strategic Developments

• In September 2021, Regenerative medicines company Locate Bio raised £10 million of equity investment in a funding round co-led by existing shareholder Mercia Asset Management and new investor BGF. This funding is aimed to advance the regenerative medicine pipeline of orthobiologics
• In September 2020, ESSKA (European Society for Sports Traumatology, Knee Surgery, and Arthroscopy) launched the "Orthobiologics Initiative" (ORBIT) to support a better knowledge of the full benefits of these therapies and establish a structured path to improve their use
• In September 2020, Royal Biologics, an ortho-biologics company completed the acquisition of Fibrinet. The acquisition helped the company to add novel technologies to its portfolio of autologous and live cellular solutions to support orthopedic and spinal fusion
• In June 2020, Bioventus launched its Signafuse Bioactive Bone Graft in a new strip format and also received 510(k) clearance. These strips consist of 55% bioglass by weight and have been shown to induce higher levels of osteoblast differentiation compared to other synthetic bone graft strips
• In June 2020, Bioventus selected Bazis NN as its authorized distributor for Durolane, its single-injection joint-fluid osteoarthritis (OA) treatment

Frequently Asked Questions About This Report